ES2613055T3 - Diagnóstico de interferón de tipo 1 - Google Patents
Diagnóstico de interferón de tipo 1 Download PDFInfo
- Publication number
- ES2613055T3 ES2613055T3 ES10814513.7T ES10814513T ES2613055T3 ES 2613055 T3 ES2613055 T3 ES 2613055T3 ES 10814513 T ES10814513 T ES 10814513T ES 2613055 T3 ES2613055 T3 ES 2613055T3
- Authority
- ES
- Spain
- Prior art keywords
- ifnα
- type
- genes
- ifi44
- rsad2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010050904 Interferons Proteins 0.000 title claims abstract description 250
- 102000014150 Interferons Human genes 0.000 title claims abstract description 247
- 229940079322 interferon Drugs 0.000 title claims abstract description 246
- 238000003745 diagnosis Methods 0.000 title description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 282
- 230000014509 gene expression Effects 0.000 claims abstract description 231
- 238000000034 method Methods 0.000 claims abstract description 181
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 claims abstract description 179
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims abstract description 179
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims abstract description 179
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 claims abstract description 179
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims abstract description 179
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims abstract description 179
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims abstract description 178
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims abstract description 178
- 230000000694 effects Effects 0.000 claims abstract description 137
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 106
- 201000010099 disease Diseases 0.000 claims abstract description 67
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 41
- 230000008859 change Effects 0.000 claims abstract description 40
- 230000001064 anti-interferon Effects 0.000 claims abstract description 32
- 108020003175 receptors Proteins 0.000 claims abstract description 23
- 102000005962 receptors Human genes 0.000 claims abstract description 22
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract description 20
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 88
- 229950010077 sifalimumab Drugs 0.000 claims description 79
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical group C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 claims description 79
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 28
- 108091034117 Oligonucleotide Proteins 0.000 claims description 25
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 24
- 239000002299 complementary DNA Substances 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 13
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 11
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 11
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 4
- 108020004463 18S ribosomal RNA Proteins 0.000 claims description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 160
- 230000001939 inductive effect Effects 0.000 description 158
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 description 156
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 description 156
- 239000000523 sample Substances 0.000 description 89
- 239000003795 chemical substances by application Substances 0.000 description 82
- 239000003814 drug Substances 0.000 description 68
- 201000001981 dermatomyositis Diseases 0.000 description 67
- 229940124597 therapeutic agent Drugs 0.000 description 66
- 230000001105 regulatory effect Effects 0.000 description 64
- 239000000902 placebo Substances 0.000 description 60
- 229940068196 placebo Drugs 0.000 description 60
- 230000009467 reduction Effects 0.000 description 57
- 208000005987 polymyositis Diseases 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 43
- 108020004414 DNA Proteins 0.000 description 39
- 208000035475 disorder Diseases 0.000 description 39
- 230000004044 response Effects 0.000 description 37
- 206010039073 rheumatoid arthritis Diseases 0.000 description 37
- 230000009885 systemic effect Effects 0.000 description 36
- 239000013615 primer Substances 0.000 description 32
- 208000021386 Sjogren Syndrome Diseases 0.000 description 30
- 108091033319 polynucleotide Proteins 0.000 description 27
- 102000040430 polynucleotide Human genes 0.000 description 27
- 239000002157 polynucleotide Substances 0.000 description 27
- 230000003827 upregulation Effects 0.000 description 27
- 208000023275 Autoimmune disease Diseases 0.000 description 25
- 206010039710 Scleroderma Diseases 0.000 description 25
- 101000644847 Homo sapiens Ubl carboxyl-terminal hydrolase 18 Proteins 0.000 description 24
- 102100020726 Ubl carboxyl-terminal hydrolase 18 Human genes 0.000 description 24
- 230000009266 disease activity Effects 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 20
- 230000002018 overexpression Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 238000002405 diagnostic procedure Methods 0.000 description 16
- 239000003550 marker Substances 0.000 description 15
- 206010061818 Disease progression Diseases 0.000 description 14
- 239000003124 biologic agent Substances 0.000 description 14
- 230000005750 disease progression Effects 0.000 description 14
- 230000004547 gene signature Effects 0.000 description 14
- 239000013610 patient sample Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 101500014052 Rift valley fever virus (strain ZH-548 M12) NSm-Gn protein Proteins 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 241000712461 unidentified influenza virus Species 0.000 description 12
- -1 BDNK Proteins 0.000 description 11
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 11
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 description 11
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 11
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 11
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 description 11
- 239000002131 composite material Substances 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 108010085650 interferon gamma receptor Proteins 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 238000006386 neutralization reaction Methods 0.000 description 10
- 201000002481 Myositis Diseases 0.000 description 9
- 201000004681 Psoriasis Diseases 0.000 description 9
- 230000003828 downregulation Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 description 8
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 description 8
- 208000005777 Lupus Nephritis Diseases 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 description 7
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 description 7
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 description 7
- 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 description 7
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 7
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 description 7
- 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 description 7
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 7
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 description 7
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 7
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 7
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 108090000848 Ubiquitin Proteins 0.000 description 7
- 102000044159 Ubiquitin Human genes 0.000 description 7
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 7
- 239000003246 corticosteroid Substances 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 6
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 6
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102100039621 Epithelial-stromal interaction protein 1 Human genes 0.000 description 6
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 6
- 101000814134 Homo sapiens Epithelial-stromal interaction protein 1 Proteins 0.000 description 6
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 6
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 6
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 6
- 101000604998 Homo sapiens Lysosome-associated membrane glycoprotein 3 Proteins 0.000 description 6
- 101001067396 Homo sapiens Phospholipid scramblase 1 Proteins 0.000 description 6
- 101000828739 Homo sapiens SPATS2-like protein Proteins 0.000 description 6
- 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 description 6
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 6
- 101710197072 Lectin 1 Proteins 0.000 description 6
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 6
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 6
- 102100034627 Phospholipid scramblase 1 Human genes 0.000 description 6
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 6
- 102100023521 SPATS2-like protein Human genes 0.000 description 6
- 102100032855 Sialoadhesin Human genes 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 206010047115 Vasculitis Diseases 0.000 description 6
- 229960001570 ademetionine Drugs 0.000 description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 230000000723 chemosensory effect Effects 0.000 description 6
- 239000013068 control sample Substances 0.000 description 6
- 229960001334 corticosteroids Drugs 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000003712 lysosome Anatomy 0.000 description 6
- 230000001868 lysosomic effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003607 modifier Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 201000000306 sarcoidosis Diseases 0.000 description 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091027981 Response element Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 210000005222 synovial tissue Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 4
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 4
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 4
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 239000013614 RNA sample Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000003831 deregulation Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108010054267 Interferon Receptors Proteins 0.000 description 3
- 102000001617 Interferon Receptors Human genes 0.000 description 3
- 102000002227 Interferon Type I Human genes 0.000 description 3
- 108010014726 Interferon Type I Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000011223 gene expression profiling Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002077 nanosphere Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000016918 Complement C3 Human genes 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 2
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 102100038610 Myeloperoxidase Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 102100030856 Myoglobin Human genes 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 102100029812 Protein S100-A12 Human genes 0.000 description 2
- 101710110949 Protein S100-A12 Proteins 0.000 description 2
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 101710108790 Stromelysin-1 Proteins 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 102100030859 Tissue factor Human genes 0.000 description 2
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 239000003269 fluorescent indicator Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 2
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- XHSQDZXAVJRBMX-DDHJBXDOSA-N 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1 XHSQDZXAVJRBMX-DDHJBXDOSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010067982 Butterfly rash Diseases 0.000 description 1
- FBBUFUYJOZFZPJ-UHFFFAOYSA-N C(CC1)CC1C(CC1)CC1C(CC1)CCC1C(CC1)CCC1C1CCCC1 Chemical compound C(CC1)CC1C(CC1)CC1C(CC1)CCC1C(CC1)CCC1C1CCCC1 FBBUFUYJOZFZPJ-UHFFFAOYSA-N 0.000 description 1
- 0 CC1C(*)CCC1 Chemical compound CC1C(*)CCC1 0.000 description 1
- UKCAQUQDAABMJQ-UHFFFAOYSA-N CC1CC(CC2)=C2C1 Chemical compound CC1CC(CC2)=C2C1 UKCAQUQDAABMJQ-UHFFFAOYSA-N 0.000 description 1
- XARGIVYWQPXRTC-UHFFFAOYSA-N CCC1C(C)CCCC1 Chemical compound CCC1C(C)CCCC1 XARGIVYWQPXRTC-UHFFFAOYSA-N 0.000 description 1
- GURKWNMOHNXWGJ-UHFFFAOYSA-N CCCCCCCC(CCC1)CC1C(CC1)CCC1C(CCC)CCC(CC1)CC1C(CC1)CCC1C1CC(C)CCC1 Chemical compound CCCCCCCC(CCC1)CC1C(CC1)CCC1C(CCC)CCC(CC1)CC1C(CC1)CCC1C1CC(C)CCC1 GURKWNMOHNXWGJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 101150103227 IFN gene Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- YVJGIGDFHMIDFH-FTWQHDNSSA-N n-[(2s,3r,4r,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]-5-(dimethylamino)naphthalene-1-sulfonamide Chemical compound CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NS(=O)(=O)C1=CC=CC2=C(N(C)C)C=CC=C12 YVJGIGDFHMIDFH-FTWQHDNSSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 230000017239 negative regulation of gene expression Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000019532 positive regulation of gene expression Effects 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23963009P | 2009-09-03 | 2009-09-03 | |
| US239630P | 2009-09-03 | ||
| PCT/US2010/047721 WO2011028933A1 (en) | 2009-09-03 | 2010-09-02 | Type 1 interferon diagnostic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2613055T3 true ES2613055T3 (es) | 2017-05-22 |
Family
ID=43649646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10814513.7T Active ES2613055T3 (es) | 2009-09-03 | 2010-09-02 | Diagnóstico de interferón de tipo 1 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20120251546A1 (enExample) |
| EP (1) | EP2473636B1 (enExample) |
| JP (2) | JP5727484B2 (enExample) |
| KR (1) | KR20120101340A (enExample) |
| CN (1) | CN102753704A (enExample) |
| AU (1) | AU2010289383B2 (enExample) |
| BR (1) | BR112012004781A2 (enExample) |
| CA (1) | CA2772921A1 (enExample) |
| CY (1) | CY1118566T1 (enExample) |
| DK (1) | DK2473636T3 (enExample) |
| ES (1) | ES2613055T3 (enExample) |
| HR (1) | HRP20170091T1 (enExample) |
| HU (1) | HUE032917T2 (enExample) |
| LT (1) | LT2473636T (enExample) |
| ME (1) | ME02599B (enExample) |
| MX (1) | MX2012002640A (enExample) |
| PL (1) | PL2473636T3 (enExample) |
| PT (1) | PT2473636T (enExample) |
| RS (1) | RS55641B1 (enExample) |
| RU (1) | RU2012112802A (enExample) |
| SI (1) | SI2473636T1 (enExample) |
| SM (2) | SMT201700063T1 (enExample) |
| WO (1) | WO2011028933A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003237889A1 (en) * | 2002-06-11 | 2003-12-22 | Idaho Research Foundation | Type i interferon-inducible proteins to detect viral infection |
| EP2077858A4 (en) * | 2006-12-06 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS |
| JP2010526107A (ja) * | 2007-05-03 | 2010-07-29 | メディミューン，エルエルシー | 自己免疫疾患の自己抗体マーカー |
| EP2701742A4 (en) * | 2011-04-26 | 2015-03-18 | Genentech Inc | COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES |
| WO2013101771A2 (en) * | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| US9493570B2 (en) * | 2012-06-13 | 2016-11-15 | Medimmune, Llc | Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies |
| JP6531306B2 (ja) * | 2015-02-20 | 2019-06-19 | 一三 西野 | 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法 |
| CN105316404B (zh) * | 2015-02-27 | 2017-02-22 | 中南大学湘雅二医院 | 系统性红斑狼疮生物标志物及其诊断试剂盒 |
| MX2018010771A (es) | 2016-03-10 | 2019-05-15 | Viela Bio Inc | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. |
| CN105567861B (zh) * | 2016-03-16 | 2018-12-14 | 宫蕊 | Ifi27作为冠心病诊断标志物的用途 |
| WO2020165437A1 (en) * | 2019-02-15 | 2020-08-20 | Astrazeneca Ab | Type i interferon-mediated disorders |
| EP4058060B1 (en) | 2019-11-11 | 2025-02-19 | Astrazeneca AB | Type i interferon inhibition in systemic lupus erythematosus |
| EP4566667A3 (en) | 2020-05-29 | 2025-09-03 | AstraZeneca AB | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling |
| CN116234553A (zh) * | 2020-10-02 | 2023-06-06 | 新基公司 | 治疗系统性红斑狼疮的方法和作为对疗法临床敏感性的预测指标的生物标志物的用途 |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| AU2021383537A1 (en) | 2020-11-18 | 2023-06-29 | Astrazeneca Ab | Steroid sparing |
| PL4192882T3 (pl) | 2021-04-23 | 2025-04-28 | Astrazeneca Ab | Leczenie toczniowego zapalenia nerek przeciwciałem przeciwko receptorowi typu i inf anifrolumabem |
| EP4326322A1 (en) | 2021-04-23 | 2024-02-28 | Astrazeneca AB | Treatment of cutaneous lupus erythematous |
| KR20250092298A (ko) | 2021-04-23 | 2025-06-23 | 아스트라제네카 아베 | 피하 주사용 항-ifnar1 투여 요법 |
| EP4333877A1 (en) * | 2021-05-04 | 2024-03-13 | Viela Bio, Inc. | Methods of treatment of autoimmune disorders using ilt7 binding proteins |
| EP4337696A1 (en) | 2021-05-12 | 2024-03-20 | Astrazeneca AB | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients |
| CA3226744A1 (en) | 2021-07-27 | 2023-02-02 | Astrazeneca Ab | Treatment of lupus |
| KR20240082399A (ko) | 2021-10-04 | 2024-06-10 | 아스트라제네카 아베 | 루푸스의 치료 |
| AU2023339761A1 (en) | 2022-09-14 | 2025-03-20 | Viatris Asia Pacific Pte. Ltd. | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
| JP2025533978A (ja) | 2022-10-13 | 2025-10-09 | アストラゼネカ・アクチエボラーグ | ループスの治療 |
| WO2024241156A1 (en) | 2023-05-19 | 2024-11-28 | Astrazeneca Ab | Treatment of lupus |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
| GB202402824D0 (en) | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60500864A (ja) | 1983-02-04 | 1985-06-06 | ワドリ、テクナラジズ、インコーパレイティド | 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ |
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| US4885166A (en) | 1985-06-11 | 1989-12-05 | Ciba-Geigy Corporation | Hybrid interferons |
| US7247425B2 (en) * | 1998-01-30 | 2007-07-24 | Evolutionary Genomics, Llc | Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| AU2004293369A1 (en) * | 2003-03-03 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the treatment of systemic lupus erythematosis |
| CA2458085A1 (en) * | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
| CN1795010A (zh) | 2003-04-23 | 2006-06-28 | 梅达雷克斯公司 | 针对α干扰素受体－1(IFNAR－1)的人源化抗体 |
| SI2418220T1 (sl) | 2003-12-10 | 2017-10-30 | E. R. Squibb & Sons, L.L.C. | Interferon alfa protitelesa in njihova uporaba |
| EP1730308A4 (en) * | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS |
| PT1781705E (pt) | 2004-06-21 | 2014-12-23 | Medarex Llc | Anticorpos contra recetor i do interferão alfa e as suas utilizações |
| PT2327792E (pt) * | 2005-08-05 | 2013-11-21 | Genentech Inc | Métodos e composições para a detecção de distúrbios autoimunes |
| US8211649B2 (en) * | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
| WO2008016356A2 (en) * | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
| EP2077858A4 (en) * | 2006-12-06 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS |
| JP2010526107A (ja) * | 2007-05-03 | 2010-07-29 | メディミューン，エルエルシー | 自己免疫疾患の自己抗体マーカー |
| US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| CA2714410A1 (en) * | 2008-02-08 | 2009-08-13 | Medimmune, Llc | Disease markers and uses thereof |
| WO2009130176A1 (en) * | 2008-04-21 | 2009-10-29 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Antiviral Therapy |
| US20090325176A1 (en) * | 2008-06-05 | 2009-12-31 | Wyeth | Gene Expression Profiles Associated with Asthma Exacerbation Attacks |
-
2010
- 2010-09-02 HU HUE10814513A patent/HUE032917T2/hu unknown
- 2010-09-02 EP EP10814513.7A patent/EP2473636B1/en active Active
- 2010-09-02 LT LTEP10814513.7T patent/LT2473636T/lt unknown
- 2010-09-02 WO PCT/US2010/047721 patent/WO2011028933A1/en not_active Ceased
- 2010-09-02 JP JP2012528058A patent/JP5727484B2/ja not_active Expired - Fee Related
- 2010-09-02 ME MEP-2017-24A patent/ME02599B/me unknown
- 2010-09-02 BR BR112012004781A patent/BR112012004781A2/pt not_active IP Right Cessation
- 2010-09-02 ES ES10814513.7T patent/ES2613055T3/es active Active
- 2010-09-02 MX MX2012002640A patent/MX2012002640A/es not_active Application Discontinuation
- 2010-09-02 CN CN2010800447566A patent/CN102753704A/zh active Pending
- 2010-09-02 RU RU2012112802/10A patent/RU2012112802A/ru not_active Application Discontinuation
- 2010-09-02 PL PL10814513T patent/PL2473636T3/pl unknown
- 2010-09-02 SM SM20170063T patent/SMT201700063T1/it unknown
- 2010-09-02 HR HRP20170091TT patent/HRP20170091T1/hr unknown
- 2010-09-02 SI SI201031376A patent/SI2473636T1/sl unknown
- 2010-09-02 US US13/393,616 patent/US20120251546A1/en not_active Abandoned
- 2010-09-02 PT PT108145137T patent/PT2473636T/pt unknown
- 2010-09-02 CA CA2772921A patent/CA2772921A1/en not_active Abandoned
- 2010-09-02 DK DK10814513.7T patent/DK2473636T3/en active
- 2010-09-02 AU AU2010289383A patent/AU2010289383B2/en not_active Ceased
- 2010-09-02 RS RS20170089A patent/RS55641B1/sr unknown
- 2010-09-02 KR KR1020127008547A patent/KR20120101340A/ko not_active Withdrawn
-
2015
- 2015-03-18 US US14/662,134 patent/US20150191788A1/en not_active Abandoned
- 2015-04-02 JP JP2015075518A patent/JP2015147788A/ja active Pending
- 2015-10-06 US US14/876,549 patent/US20160024205A1/en not_active Abandoned
-
2017
- 2017-01-26 SM SM201700063T patent/SMT201700063B/it unknown
- 2017-01-26 CY CY20171100112T patent/CY1118566T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102753704A (zh) | 2012-10-24 |
| CY1118566T1 (el) | 2017-07-12 |
| LT2473636T (lt) | 2017-02-10 |
| US20120251546A1 (en) | 2012-10-04 |
| BR112012004781A2 (pt) | 2017-02-14 |
| PL2473636T3 (pl) | 2017-05-31 |
| EP2473636B1 (en) | 2016-10-26 |
| PT2473636T (pt) | 2017-02-06 |
| RS55641B1 (sr) | 2017-06-30 |
| RU2012112802A (ru) | 2013-10-10 |
| ME02599B (me) | 2017-06-20 |
| US20160024205A1 (en) | 2016-01-28 |
| CA2772921A1 (en) | 2011-03-10 |
| JP2013503642A (ja) | 2013-02-04 |
| DK2473636T3 (en) | 2017-02-06 |
| WO2011028933A1 (en) | 2011-03-10 |
| EP2473636A4 (en) | 2013-02-27 |
| AU2010289383B2 (en) | 2015-04-16 |
| JP5727484B2 (ja) | 2015-06-03 |
| EP2473636A1 (en) | 2012-07-11 |
| HRP20170091T1 (hr) | 2017-03-24 |
| AU2010289383A1 (en) | 2012-04-19 |
| MX2012002640A (es) | 2012-06-25 |
| HUE032917T2 (hu) | 2017-11-28 |
| JP2015147788A (ja) | 2015-08-20 |
| US20150191788A1 (en) | 2015-07-09 |
| SI2473636T1 (sl) | 2017-04-26 |
| SMT201700063T1 (it) | 2017-03-08 |
| SMT201700063B (it) | 2017-03-08 |
| KR20120101340A (ko) | 2012-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2613055T3 (es) | Diagnóstico de interferón de tipo 1 | |
| Atreya et al. | Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF? | |
| JP5411129B2 (ja) | インターフェロンα誘導性薬力学的マーカー | |
| KR101532797B1 (ko) | 인터페론 알파 유도성 약력학적 마커 | |
| ES2529593T3 (es) | Marcadores de enfermedades y usos de los mismos | |
| US20110287022A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| CN101594882A (zh) | 干扰素α诱导的药代动力学标记物 | |
| Okumura et al. | Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells | |
| CN113508138B (zh) | I型干扰素介导的障碍 | |
| US20100261172A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| WO2009155559A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| AU2014200127A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| AU2014200128A1 (en) | Interferon alpha-induced pharmacodynamic markers |